Document Detail


High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer.
MedLine Citation:
PMID:  2942246     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifty heavily pretreated postmenopausal patients with advanced breast cancer were treated with oral medroxyprogesterone acetate (1 g) daily for 1-18 months. Eight patients (16%) responded to treatment for periods up to 18 months and in an additional eight patients (16%) the disease stabilized for up to 10 months. Thirty-two patients (64%) developed adverse effects and eight (16%), all of whom had extensive pulmonary metastases, died a respiratory-related death thought possibly to have been brought on or accelerated by treatment. Only eight patients (16%) experienced increased appetite, weight gain, feeling of wellbeing, or improved performance status. We conclude that medroxyprogesterone acetate is useful in patients with advanced metastatic disease but should be restricted to carefully selected patients and used only with extreme caution in patients with underlying cardiovascular or respiratory disease. Its major application probably lies in the benefit it confers earlier in the disease.
Authors:
P E Goss; S Ashley; T J Powles; R C Coombes
Related Documents :
19427196 - Developing a ctcaes patient questionnaire for late toxicity after head and neck radioth...
15596916 - Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic e...
16411206 - Topotecan and cyclophosphamide in patients with refractory or relapsed ewing tumors.
23872816 - An update on ocular involvement in mucopolysaccharidoses.
25418286 - Rehabilitation of the sarcoma patient-enhancing the recovery and functioning of patient...
2168306 - Aldosterone control in critically ill patients: acth, metoclopramide, and atrial natriu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer treatment reports     Volume:  70     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1986 Jun 
Date Detail:
Created Date:  1986-09-18     Completed Date:  1986-09-18     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  777-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Breast Neoplasms / drug therapy*,  pathology
Edema / chemically induced
Female
Humans
Medroxyprogesterone / adverse effects,  analogs & derivatives*,  therapeutic use
Medroxyprogesterone Acetate
Middle Aged
Neoplasm Metastasis
Respiration Disorders / chemically induced
Chemical
Reg. No./Substance:
520-85-4/Medroxyprogesterone; 71-58-9/Medroxyprogesterone Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase II clinical evaluation of doxifluridine.
Next Document:  Congenital malformations of the central nervous system in a 1-year birth cohort followed to the age ...